Arabic Arabic English English French French German German
dark

Kinnate Biopharma Inc. Presents Preclinical Data on its Lead FGFR Inhibitor Candidate at the JCA-AACR Precision Cancer Medicine International Conference

Kinnate Biopharma Inc. announced results from preclinical studies evaluating its lead Fibroblast Growth Factor Receptor (FGFR) inhibitor candidate, KIN-3248. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

ClearDATA Partners with Interlace Health to Safeguard Data for Zero-Touch Patient Intake Solution

Next Post

Transgene Announces Upcoming Investor Meetings – Sep 13, 2021

Related Posts
Total
0
Share